Population genetics and drug resistance markers: An essential for malaria surveillance in pakistan

Journal of the College of Physicians and Surgeons Pakistan

Volumn 23, Issue 12, 2013, Pages 878-884

  Raza, Afsheen ^a   Beg, Mohammad Asim ^a  

^a AGA KHAN UNIVERSITY   (Pakistan)

Author keywords

Circumsporozoite protein (csp); Drug resistance markers; Genetic diversity; Malaria; Merozoite surface protein 1 (msp 1); Plasmodium vivax

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; MALARIA VACCINE; PYRIMETHAMINE PLUS SULFADOXINE; SULFADOXINE;

CSP GENE; GENE; GENE IDENTIFICATION; GENETIC MARKER; GENETIC VARIABILITY; HUMAN; INFECTION CONTROL; MALARIA; MSP 1 GENE; NONHUMAN; PAKISTAN; PLASMODIUM VIVAX; POPULATION GENETICS; POPULATION STRUCTURE; REVIEW; SURVIVAL;

ANTIMALARIALS; DRUG RESISTANCE; GENETIC MARKERS; GENETIC VARIATION; GENETICS, POPULATION; HUMANS; MALARIA, VIVAX; MEROZOITE SURFACE PROTEIN 1; PAKISTAN; PLASMODIUM VIVAX; PROTOZOAN PROTEINS; SEQUENCE ANALYSIS;

EID: 84890067811     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Center for Disease Control and Prevention. Malaria [Internet]. 2012. Available from: http://www.cdc.gov/malaria
2. Guerra CA, Hay SI. Mapping the global extent of malaria in 2005. Trends Parasitol 2006;22:353-8.
3. World Health Organization, World malaria report 2012 [Internet]. 2013. Available from: http://www.who.int/malaria/ publications/world_malaria_report_2012/en/
4. Kakar Q, Bile KM. Malaria control in Pakistan: new tools at hand but challenging epidemiological realities. East Mediterr Health J 2010;16:54-60.
5. WHO. WHO guidelines for the treatment of malaria [Internet]. 2010. Available from: http://whqlibdoc.who.int/publications
6. Raza A, Ghanchi NK, Thaver AM, Jafri S, Beg MA. Genetic diversity of Plasmodium vivax clinical isolates from southern Pakistan using pvcsp and pvmsp-1 genetic markers. Malaria J 2013;12:16.
7. Krämer A, Kretzschmar M, Krickeberg K, editors. Modern infectious disease epidemiology: concepts, methods, mathematical models, and public health. New York: Springer;2010.
8. Genetic diversity [Internet]. 2010. Available from: en.wikipedia.org/ wiki/Genetic_diversity
9. Escalante AA, Rojas A, Udhayakumar V, Lal AA. Assessing the effect of natural selection in malaria parasites. Trends Parasitol 2004;20:388-95.
10. Peyerl-Hoffmann G, Jelinek T, Kilian A, Kabagambe G, Metzger WG, von Sonnenburg F. Genetic diversity of Plasmodium falciparum and its relationship to parasite density in an area with different malaria endemicities in West Uganda. Trop Med Int Health 2001;6: 607-13.
11. de Souza-Neiras WC, de Melo LM, Machado RL. The genetic diversity of Plasmodium vivax: a review. Mem Inst Oswaldo Cruz 2007;102:245-54.
12. Putaporntip C, Jongwutiwes S, Sakihama N, Ferreira MU, Kho WG, Kaneko A, et al. Mosaic organization and heterogeneity in frequency of allelic recombination of the Plasmodium vivax merozoite surface protein-1 locus. Proc Natl Acad Sci USA 2002;99:16348-53.
13. Cui L, Escalante AA, Imwong M, Snounou G. The genetic diversity of Plasmodium vivax populations. Trends Parasitol 2003;19:220-26.
14. Zakeri S, Abouie Mehrizi A, Djadid ND, Snounou G. Circumsporozoite protein gene diversity among temperate and tropical Plasmodium vivax isolates from Iran. Trop Med Int Health 2006;11:729-37.
15. Imwong M, Pukrittayakamee S, Grüner AC, Rénia L, Letourneur F, Looareesuwan S, et al. Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp-1. Malaria J 2005;4:20.
16. Zakeri S, Raeisi A, Afsharpad M, Kakar Q, Ghasemi F, Atta H, et al. Molecular characterization of Plasmodium vivax clinical isolates in Pakistan and Iran using pvmsp-1, pvmsp-3 alpha and pvcsp genes as molecular markers. Parasitol Int 2010; 59:15-21. Epub 2009 Jun 21.
17. Zakeri S, Afsharpad M, Ghasemi F, Raeisi A, Safi N, Butt W, et al. Molecular surveillance of Plasmodium vivax dhfr and dhps mutations in isolates from Afghanistan. Malar J 2010;9:75.
18. Kim JR, Imwong M, Nandy A, Chotivanich K, Nontprasert A, Tonomsing N, et al. Genetic diversity of Plasmodium vivax in Kolkata, India. Malaria J 2006;5:71.
19. Dhangadamajhi G, Rout BK, Kar SK, Ranjit MR. Genetic diversity of Plasmodium vivax in a hyperendemic area predominated by Plasmodium falciparum;a preliminary study. Trop Biomed 2010;27:578-84.
20. Zakeri S, Safi N, Afsharpad M, Butt W, Ghasemi F, Mehrizi AA, et al. Genetic structure of Plasmodium vivax isolates from two malaria endemic areas in Afghanistan. Acta Trop 2010;113:12-9. Epub 2009 Aug 28.
21. Souza-Neiras WC, Storti-Melo LM, Cassiano GC, Couto VS, Couto AA, Soares IS, et al. Plasmodium vivax circumsporozoite genotypes: a limited variation or new subspecies with major biological consequences? Malaria J 2010;9:178.
22. Arévalo-Herrera M, Vera O, Castellanos A, Céspedes N, Soto L, Corradin G, et al. Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in montanide ISA 720 and montanide ISA 51 adjuvants. Am J Trop Med Hyg 2011;84:21-7.
23. Maestre A, Sunil S, Ahmad G, Mohmmed A, Echeverri M, Corredor M, et al. Inter-allelic recombination in the Plasmodium vivax merozoite surface protein 1 gene among Indian and Colombian isolates. Malaria J 2004;3:4.
24. Storti-Melo LM, Souza-Neiras WC, Cassiano GC, Taveira LC, Cordeiro AJ, Couto VS, et al. Evaluation of the naturally acquired antibody immune response to the Pv200L N-terminal fragment of Plasmodium vivax merozoite surface protein-1 in four areas of the Amazon Region of Brazil. Am J Trop Med Hyg 2011;84:58-63.
25. Valencia SH, Rodríguez DC, Acero DL, Ocampo V, Arévalo-Herrera M. Platform for Plasmodium vivax vaccine discovery and development. Mem Inst Oswaldo Cruz 2011;106:179-92.
26. Arévalo-Herrera M, Chitnis C, Herrera S. Current status of Plasmodium vivax vaccine. Hum Vaccin 2010;6:124-32. Epub 2010 Jan 26.
27. Garg S, Saxena V, Lumb V, Pakalapati D, Boopathi PA, Subudhi AK, et al. Novel mutations in the antifolate drug resistance marker genes among Plasmodium vivax isolates exhibiting severe manifestations. Exp Parasito 2012;132:410-6.
28. Hawkins VN, Auliff A, Prajapati SK, Rungsihirunrat K, Hapuarachchi HC, Maestre A, et al. Multiple origins of resistance-conferring mutations in Plasmodium vivax dihydrofolate reductase. Malaria J 2008;7:72.
29. Hawkins VN, Joshi H, Rungsihirunrat K, Na-Bangchang K, Sibley CH. Antifolates can have a role in the treatment of Plasmodium vivax. Trends Parasitol 2007;23:213-22. Epub 2007 Mar 26.
30. Alam MT, Bora H, Bharti PK, Saifi MA, Das MK, Dev V, et al. Similar trends of pyrimethamine resistance-associated mutations in Plasmodium vivax and P. falciparum. Antimicrob Agents Chemother 2007;51:857-63.
31. Barnadas C, Tichit M, Bouchier C, Ratsimbasoa A, Randrianasolo L, Raherinjafy R, et al. Plasmodium vivax dhfr and dhps mutations in isolates from Madagascar and therapeutic response to sulphadoxine-pyrimethamine. Malaria J 2008;7:35.
32. Khatoon L, Baliraine FN, Bonizzoni M, Malik SA, Yan G. Prevalence of antimalarial drug resistance mutations in Plasmodium vivax and P. falciparum from a malaria-endemic area of Pakistan. Am J Trop Med Hyg 2009;81:525-8.
33. Zakeri S, Afsharpad M, Ghasemi F, Raeisi A, Kakar Q, Atta H, et al. Plasmodium vivax: prevalence of mutations associated with sulfadoxine-pyrimethamine resistance in Plasmodium vivax clinical isolates from Pakistan. Exp Parasitol 2011;127:167-72. Epub 2010 Jul 23.
34. Leslie T, Mayan MI, Hasan MA, Safi MH, Klinkenberg E, Whitty CJ, et al. Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or chloroquine for the treatment of Plasmodium vivax malaria in Afghanistan and Pakistan: a randomized controlled trial. JAMA 2007;297:2201-9.
35. Ferone R. Folate metabolism in malaria. Bull World Health Organ 1977;55:291-8.
36. White NJ. Drug resistance in malaria. Br Med Bull 1998;54:703-15.
37. Koenderink JB, Kavishe RA, Rijpma SR, Russel FG. The ABCs of multidrug resistance in malaria. Trends Parasitol 2010;26:440-6. Epub 2010 Jun 11.
38. Pagon RA, Dolan CR, editors. Gene reviews [Internet]. Seattle (WA): University of Washington;1993. Available from: http:// www.ncbi.nlm.nih.gov/books/NBK1116/
39. Gregson A, Plowe CV. Mechanisms of resistance of malaria parasites to antifolates. Pharmacol Rev 2005;57:117-45.
40. Auliff A, Wilson DW, Russell B, Gao Q, Chen N, Anhle N, et al. Amino acid mutations in Plasmodium vivax DHFR and DHPS from several geographical regions and susceptibility to antifolate drugs. Am J Trop Med Hyg 2006;75:617-21.
41. Arévalo-Herrera M, Roggero MA, Gonzalez JM, Vergara J, Corradin G, López JA, et al. Mapping and comparison of the Bcell epitopes recognized on the Plasmodium vivax circumsporozoite protein by immune Colombians and immunized Aotus monkeys. Ann Trop Med Parasitol 1998;92:539-51.
42. Arévalo-Herrera M, Valencia AZ, Vergara J, Bonelo A, Fleischhauer K, González JM, et al. Identification of HLA-A2 restricted CD8(+) T-lymphocyte responses to Plasmodium vivax circumsporozoite protein in individuals naturally exposed to malaria. Parasite Immunol 2002;24:161-9.
43. Arnot DE, Barnwell JW, Tam JP, Nussenzweig V, Nussenzweig RS, Enea V. Circumsporozoite protein of Plasmodium vivax: gene cloning and characterization of the immunodominant epitope. Science 1985;230:815-8.